Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.69 |
| ▸ | CXCR3 | P49682 | 14/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639747 | 1.00 | CCR1 (0.69) | CCR1CXCR3KCNH2 | |
| SCHEMBL1637786 | 0.94 | CCR1 (0.79) | CCR1CXCR3 | |
| SCHEMBL1639057 | 0.94 | CCR1 (0.79) | CCR1CXCR3 | |
| SCHEMBL1637790 | 0.94 | CCR1 (0.79) | CCR1CXCR3 | |
| SCHEMBL1690944 | 0.92 | CCR1 (0.66) | CCR1CXCR3 | |
| SCHEMBL1639478 | 0.92 | CCR1 (0.66) | CCR1CXCR3 | |
| SCHEMBL12624494 | 0.92 | CCR1 (0.59) | CCR1CXCR3KCNH2 | |
| SCHEMBL22911381 | 0.90 | CCR1 (0.64) | CCR1CXCR3KCNH2 | |
| SCHEMBL10063575 | 0.90 | CCR1 (0.64) | CCR1CXCR3KCNH2 | |
| SCHEMBL1638044 | 0.88 | CCR1 (0.87) | CCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155203-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3439653-B1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX INC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-2155203-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8481545-B2 | 3-(imidazolyl)-pyrazolo[3,4-b] pyridines | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100173911-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010051561-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2155712-A1 | 3-(IMIDAZOLYL)-PYRAZOLOÝ3,4-B¨PYRIDINES | ChemoCentryx Inc (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2155203-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7629344-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2008147815-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885KCNH2 4405/4885 |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 15/4885KCNH2 4629/4885 |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 15/4885KCNH2 4629/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 15/4885KCNH2 4629/4885 |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885KCNH2 4405/4885 |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | SOST, VDR, PTH1R | CCR1 1499/4885CXCR3 314/4885KCNH2 2862/4885 |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 15/4885KCNH2 4629/4885 |
| US-20100173911-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885KCNH2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.